跳至主要内容
临床试验/KCT0002222
KCT0002222招募中未知

Occurrence of Anti-drug antibody and change of drug level for 1 year after CT-P13 therapy and their Impact on clinical outcomes in moderate to Severe inflammatory bowel disease

Kangbuk Samsung Medical Center0 个研究点目标入组 300 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
入组人数
300

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational Study

入排标准

年龄范围
20(Year) 至 o Limit(—)
性别
All

入选标准

  • 1) Moderate to severe active Inflammatory Bowel Disease
  • [Moderate to severe criteria]
  • -Crohn's disease: CDAI score = 220, Ulcerative colitis: Mayo score = 6
  • 2) Over 19 years of age
  • 3) Anti-TNF naive
  • 4) Patients who voluntarily signed a consent form

排除标准

  • 1) A foreigner
  • 2) A history of hypersensitivity to humanized proteins
  • 3) Tuberculosis infection
  • 4) Chronic hepatitis B not being treated
  • 5) HIV infection or positive
  • 6) NYHA class III/IV heart disease
  • 7) Infection, Malignant tumor, Previous history of dysplasia of the colon or small intestine within the previous 5 years
  • 8) Pregnant women, lactating women

研究者

相似试验